How to treat after Helicobacter pylori eradication failure?;Quel traitement peut-on proposer aprés un échec d'éradication de Helicobacter pylori?

Gastroenterologie Clinique et Biologique

Volumn 27, Issue 3 II, 2003, Pages 478-483

  Bruley des Varannes, Stanislas ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR;

AGE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL STRAIN; ERADICATION THERAPY; FRANCE; GASTROINTESTINAL INFECTION; HELICOBACTER PYLORI; HUMAN; PATIENT COMPLIANCE; PRESCRIPTION; REVIEW; SMOKING HABIT; TREATMENT FAILURE;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; PENICILLINS; RECURRENCE; RIFABUTIN;

EID: 0037362177     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Dupas JL. Comment éradiquer Helicobacter pylori en première intention en France? Gastroenterol Clin Biol 2003.
2. Labenz J. Protagonist: Should we eradicate Helicobacter pylori before long term antireflux therapy? Gut 2001;49:614-6.
3. Pantoflickova D, Blum AL. Antagonist: should we eradicate Helicobacter pylori in non-ulcer dyspepsia? Gut 2001;48:758-9.
4. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999;13:1047-55.
5. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000;45:68-76.
6. van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999;94:1751-9.
7. Mégraud F. Resistance of Helicobacter pylori to antibiotics. In: Scarpignato C, Bianchi Porro G, eds. Clinical pharmacology and therapy of Helicobacter pylori infection. Prog Basic Clin Pharmacol. Basel: Karger 1999;11:329-45.
8. Mégraud F. Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy. Eur J Gastroenterol Hepatol 1999;11:S35-7.
9. Lind T, Mégraud F, Unge P, Bayerdorffer E, O'morain C, Spiller R et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116:248-53.
10. Deltenre M, Ntounda R, Jonas C, De Koster E. Eradication of Helicobacter pylori: why does it fail? Ital J Gastroenterol Hepatol 1998;30:S326-S328.
11. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493-6.
12. Huang JQ, Hunt RH. Treatment after failure: the problem of "non-responders". Gut 1999;45:140-4.
13. Meyer JM, Silliman NP, Wang W, Siepman NY, Sugg JE, Morris D et al. Risk factors for Helicobacterpylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002;136:13-24.
14. Parsons HK, Carter MJ, Sanders DS, Winstanley T, Lobo AJ. Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther 2001;15:1473-8.
15. Delchier JC, Roudot-Thoraval F, Courilion-Mallet A, Lamouliatte H, Brousse JF, Bretagne JF et al. Traitement de l'infection à Helicobacter pylori en pratique courante: résultats d'une enquête multicentrique nationale (abstract). Gastroenterol Clin Biol 2001;25:A8.
16. Sheu BS, Yang HB, Su IJ, Shiesh SC, Chi CH, Lin XZ. Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer. Gastrointest Endosc 1996;44:683-8.
17. Kamada T, Haruma K, Komoto K, Mihara M, Chen X, Yoshihara M et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter 1999;4:204-10.
18. Perri F, Villani MR, Quitadamo M, Annese V, Niro GA, Andriulli A. Ranitidine bismuth citrate-based triple therapies after failure of the standard "Maastricht triple therapy": a promising alternative to the quadruple therapy? Aliment Pharmacol Ther 2001;15:1017-22.
19. Broutet N, Marais A, Lamouliatte H, de Mascarel A, Samoyeau R, Salamon R et al. CagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia. J Clin Microbiol 2001;39:1319-22.
20. Lin CK, Hsu PI, Lai KH, Lo GH, Tseng HH, Lo CC et al. One-week quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy. J Clin Gastroenterol 2002;34:547-51.
21. Huang AH, Sheu BS, Yang HB, Huang CC, Wu JJ, Lin XZ. Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy. J Formos Med Assoc 2000;99:704-9.
22. Bontems P, Devaster JM, Corvaglia L, Dezsofi A, Van Den BC, Goutier S et al. Twelve year observation of primary and secondary antibiotic-resistant Helicobacter pylori strains in children. Pediatr Infect Dis J 2001;20:1033-8.
23. Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002;16:1933-8.
24. Queiroz DM, Dani R, Silva LD, Santos A, Moreira LS, Rocha GA et al. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol 2002;35:315-20.
25. Kato S, Fujimura S, Udagawa H, Shimizu T, Maisawa S, Ozawa K et al. Antibiotic resistance of Helicobacter pylori strains in Japanese children. J Clin Microbiol 2002;40:649-53.
26. van der Hulst RW, Weel JF, Verheul SB, Keller JJ, Ten Kate FJ, van der EA et al. Treatment of Helicobacter pylori infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatment. Aliment Pharmacol Ther 1996;10:165-71.
27. van Doorn LJ, Schneeberger PM, Nouhan N, Plaisier AP, Quint WG, de Boer WA. Importance of Helicobacter pylori CagA and VacA status for the efficacy of antibiotic treatment. Gut 2000;46:321-6.
28. Treiber GG, Malfertheiner P. Negative cagA status is a risk factor for Helicobacter pylori eradication failure (abstract). Gut 2000;47:A27.
29. Tankovic J, Lamarque D, Lascols C, Soussy CJ, Delchier JC. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Aliment Pharmacol Ther 2001;15:707-13.
30. Bommelaer G, Bruley des Varannes S, Fléjou JF, Matysiak T, Poynard T, Richard A et al. Statut Cag1 et virulence des souches d'Helicobacter pylori: résultats d'une étude multicentrique prospective nationale. Gastroenterol Clin Biol 2001;25:1084-9.
31. van der Hulst R, Tytgat G. Treatment of Helicobacter pylori eradication failure. In: Scarpignato C, Bianchi Porro G, eds. Clinical pharmacology and therapy of Helicobacter pylori infection. Prog Basic Clin Pharmacol. Basel: Karger 1999;11:317-28.
32. Borody TJ. Helicobacter pylori eradication failure-"salvage" therapies needed. Ital J Gastroenterol Hepatol 1998;30:375-7.
33. Pilotto A, Leandro G, Franceschi M, Rassu M, Bozzola L, Furlan F et al. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Aliment Pharmacol Ther 1999;13:667-73.
34. Peitz U, Sulliga M, Wolle K, Leodolter A, Von Arnim U, Kahl S et al. High rate of post-therapeutic resistance after failure of macrolidenitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 2002;16:315-24.
35. Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocella L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002;16:1269-75.
36. Laurent J, Mégraud F, Fléjou JF, Caekaert A, Barthélémy P. A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2001;15:1787-93.
37. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A et al. Current concepts in the management of Helicobacter pylori infection- the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
38. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-57.
39. Miehlke S, Hansky K, Schneider-Brachert W, Kirsch C, Bästlein E, Haferland C et al. Treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin - prospective, randomized trial comparing 7-day rifabutin-based triple therapy with high doses omeprazole amoxicillin dual therapy (abstract). Gut 2002;51 (Suppl 3):A212.
40. Rinaldi V, Zullo A, Pugliano F, Valente C, Diana F, Attili AF. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 1997;11:929-33.
41. Gisbert JP, Boixeda D, Bermejo F, Nieves RM, Jesus HM, Angeles AM et al. Re-treatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol 1999;11:1049-54.
42. Nagahara A, Miwa H, Ohkura R, Yamada T, Sato K, Hojo M et al. Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2001;16:613-8.
43. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001;36:690-700.
44. Ali'A, Menegatti M, Gatta L, Landi F, Ricci C, Acciardi C et al. A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment. Am J Gastroenterol 1999;94:2321-3.
45. Battaglia G, Di Mario F, Vigneri S, Vianello F, Benvenuti ME, Donisi PM et al. Strategy for the retreatment of failed Helicobacter pylori eradication therapy: a case series. Ital J Gastroenterol Hepatol 1998;30:370-4.
46. Gisbert JP, Gisbert JL, Marcos S, Gravalos RG, Carpio D, Pajares JM. Seven-day "rescue" therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999;13:1311-6.
47. Gasbarrini A, Ojetti V, Armuzzi A, Branca G, Canducci F, Torre ES et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:79-83.
48. Lamouliatte H, Mégraud F, Delchier JC, Bretagne JF, Courillon-Mallet A, de Korwin JD et al. Traitement de seconde ligne après un premier échec d'éradication de Helicobacter pylori: étude prospective randomisée évaluant quatre stratégies thérapeutiques (abstract). Gastroenterol Clin Biol 2001;25:A28.
49. Rinaldi V, Zullo A, De F, V, Hassan C, Winn S, Stoppino V et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999;13:163-8.
50. Fujimura S, Kato S, Kawamura T, Watanabe A. In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults. J Antimicrob Chemother 2002;49:541-3.
51. Realdi G, Dore MP, Piana A, Atzei A, Carta M, Cugia L et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter 1999;4:106-12.
52. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based'rescue therapy'for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000;14:311-6.
53. Perri F, Festa V, Clemente R, Villani MR, Quitadamo M, Caruso N et al. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96:58-62.
54. Avidan B, Melzer E, Keller N, Bar-Meir S. The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication. Isr Med Assoc J 2001;3:163-5.
55. Kearney DJ. Retreatment of Helicobacter pylori infection after initial treatment failure. Am J Gastroenterol 2001;96:1335-9.
56. Miwa H, Kurosawa A, Nagahara A, Ohkura R, Ohkusa T, Sato N. Is susceptibility test necessary before second line treatment of H. pylori infection (abstract). Gastroenterology 2002;122:A66.
57. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998;115:1272-7.
58. Marais A, Monteiro L, Occhialini A, Pina M, Lamouliatte H, Megraud F. Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. Gut 1999;44:463-7.
59. Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Am J Gastroenterol 1999;94:725-9.